LIQUIDIA CORPORATION Capital Expenditures
LIQUIDIA CORPORATION (LQDA) reported Capital Expenditures of $14.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-12
- LIQUIDIA CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $11.23M, a 962.91% increase year-over-year.
- LIQUIDIA CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $2.83M, a 757.58% increase year-over-year.
- LIQUIDIA CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $2.04M, a 58.23% increase year-over-year.
- LIQUIDIA CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $911.00K, a 47.85% decline year-over-year.
- LIQUIDIA CORPORATION payments to acquire property, plant, and equipment for fiscal 2025 was $4.34M, a 12.39% decline from fiscal 2024.
- LIQUIDIA CORPORATION payments to acquire property, plant, and equipment for fiscal 2024 was $4.95M, a 283.64% increase from fiscal 2023.
- LIQUIDIA CORPORATION payments to acquire property, plant, and equipment for fiscal 2023 was $1.29M, a 117.91% increase from fiscal 2022.
- LIQUIDIA CORPORATION payments to acquire property, plant, and equipment for fiscal 2022 was $592.00K, a 453.27% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 3 month as first filed | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 6 month as first filed | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 9 month as first filed | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $14.06M 10-Q · filed 2026-08-12 | $16.10M derived: sum of 3 quarters · filed 2026-08-12 | $17.01M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $2.83M 10-Q · filed 2026-05-11 | $4.87M derived: sum of 2 quarters · filed 2026-05-11 | $5.78M derived: sum of 3 quarters · filed 2026-05-11 | $6.84M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.95M derived: sum of 2 quarters · filed 2026-03-05 | $4.01M derived: sum of 3 quarters · filed 2026-08-12 | $4.34M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $911.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $1.97M derived: sum of 2 quarters · filed 2026-08-12 | $2.30M 10-Q · filed 2025-11-03 | $3.59M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.39M 10-Q · filed 2026-08-12 | $2.67M derived: sum of 3 quarters · filed 2026-08-12 | $4.42M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $330.00K 10-Q · filed 2026-05-11 | $1.62M derived: sum of 2 quarters · filed 2026-05-11 | $3.37M derived: sum of 3 quarters · filed 2026-05-11 | $4.66M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.04M derived: sum of 2 quarters · filed 2026-03-05 | $4.33M derived: sum of 3 quarters · filed 2026-03-05 | $4.95M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $3.04M derived: sum of 2 quarters · filed 2025-11-03 | $3.66M 10-Q · filed 2025-11-03 | $3.87M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.91M 10-Q · filed 2025-08-12 | $2.12M derived: sum of 3 quarters · filed 2026-03-05 | $2.60M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-03-31 | $624.00K 10-Q · filed 2025-05-08 | $830.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.30M derived: sum of 3 quarters · filed 2026-03-05 | $1.55M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2023-12-31 | $206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $681.00K derived: sum of 2 quarters · filed 2026-03-05 | $924.00K derived: sum of 3 quarters · filed 2026-03-05 | $1.29M 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | $475.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $718.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.08M 10-Q · filed 2024-11-13 | $1.57M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $243.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $609.00K 10-Q · filed 2024-08-07 | $1.10M derived: sum of 3 quarters · filed 2024-08-07 | $1.19M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $366.00K 10-Q · filed 2024-05-13 | $857.00K derived: sum of 2 quarters · filed 2024-05-13 | $951.00K derived: sum of 3 quarters · filed 2024-05-13 | $958.00K derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $585.00K derived: sum of 2 quarters · filed 2024-03-13 | $592.00K derived: sum of 3 quarters · filed 2024-03-13 | $592.00K 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $101.00K derived: sum of 2 quarters · filed 2023-11-07 | $101.00K 10-Q · filed 2023-11-07 | $121.00K derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $7.00K 10-Q · filed 2023-08-10 | $27.00K derived: sum of 3 quarters · filed 2023-08-10 | $27.00K derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $20.00K derived: sum of 2 quarters · filed 2023-03-20 | $20.00K derived: sum of 3 quarters · filed 2023-03-20 | $55.00K derived: sum of 4 quarters · filed 2023-03-20 | ||||
| 2021-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $20.00K derived: sum of 2 quarters · filed 2023-03-20 | $55.00K derived: sum of 3 quarters · filed 2023-03-20 | $107.00K 10-K · filed 2023-03-20 | $107.22K 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $35.00K derived: sum of 2 quarters · filed 2022-11-08 | $87.00K 10-Q · filed 2022-11-08 | $87.24K 10-Q · filed 2021-11-03 | $125.97K derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $87.00K 10-Q · filed 2022-08-11 | $87.24K 10-Q · filed 2021-08-10 | $125.97K derived: sum of 3 quarters · filed 2022-08-11 | $248.47K derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $52.00K 10-Q · filed 2022-05-12 | $52.42K 10-Q · filed 2021-05-13 | $90.97K derived: sum of 2 quarters · filed 2022-05-12 | $213.47K derived: sum of 3 quarters · filed 2022-05-12 | $621.87K derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $38.97K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $161.47K derived: sum of 2 quarters · filed 2022-03-17 | $569.87K derived: sum of 3 quarters · filed 2022-03-17 | $752.09K 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $122.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $530.90K derived: sum of 2 quarters · filed 2021-11-03 | $713.12K 10-Q · filed 2021-11-03 | |||||
| 2020-06-30 | $408.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $590.62K 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | $182.22K 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | $1.85M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |